KALV
KalVista Pharmaceuticals, Inc.
Latest Form 4:Sale$905KbyYea Christopher (CHIEF DEVELOPMENT OFFICER) · filed May 29, 2026
KalVista Pharmaceuticals, Inc. (KALV) has 45 SEC Form 4 filings (93 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jun 11, 2026.
Inside the rolling window, 6 insiders at KalVista Pharmaceuticals, Inc. reported no open-market purchases and 40 open-market sales totaling $7.2M. The most active filer is CHIEF EXECUTIVE OFFICER Palleiko Benjamin L with 13 filings. Insiders have net sold $6.4M over the trailing 6 months. The most recent open-market filing is a sale of 33,800 shares by CHIEF DEVELOPMENT OFFICER Yea Christopher, dated May 27, 2026, worth $905K.
- Industry:Biotechnology
- CEO:Benjamin L. Palleiko
- Employees:275
- HQ:Framingham, MA, US
- IPO:2015-04-09
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7.2M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| CHIEF DEVELOPMENT OFFICER | Sale | 33,800 | $905K | May 29 | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 1,966 | $53K | May 27 | SEC ↗ | |
| Chief Commercial Officer | Sale | 1,489 | $40K | May 27 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 2,239 | $60K | May 27 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 10,926 | $293K | May 26 | SEC ↗ | |
| Chief Commercial Officer | Sale | 1,861 | $50K | May 26 | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 2,358 | $63K | May 26 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 2,685 | $72K | May 26 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,489 | $40K | May 26 | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 1,108 | $30K | May 19 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 1,032 | $28K | May 19 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 1,129 | $30K | May 19 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 3,322 | $89K | May 13 | SEC ↗ | |
| Chief Commercial Officer | Sale | 1,862 | $38K | Apr 20 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 2,686 | $54K | Apr 20 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,862 | $38K | Apr 20 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 9,550 | $193K | Apr 20 | SEC ↗ | |
Venrock Healthcare Capital Partners III, L.P.First filing | 10% Owner | Sale | 174,645 | $3.0M | Mar 27 | SEC ↗ |
Venrock Healthcare Capital Partners III, L.P.First filing | 10% Owner | Sale | 39,986 | $731K | Mar 27 | SEC ↗ |
| CHIEF EXECUTIVE OFFICER | Sale | 6,693 | $108K | Mar 10 | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 4,347 | $68K | Feb 24 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 5,354 | $83K | Feb 24 | SEC ↗ | |
| Chief Commercial Officer | Sale | 3,975 | $62K | Feb 24 | SEC ↗ | |
Piekos BrianFirst in 3 months | Chief Financial Officer | Sale | 1,767 | $28K | Feb 24 | SEC ↗ |
| CHIEF EXECUTIVE OFFICER | Sale | 10,034 | $156K | Feb 24 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 1,163 | $17K | Feb 19 | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 1,109 | $17K | Feb 19 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 1,038 | $16K | Feb 19 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 3,354 | $53K | Feb 13 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 7,294 | $120K | Dec 9 | SEC ↗ | |
Sweeny NicoleFirst filing | Chief Commercial Officer | Sale | 3,813 | $51K | Dec 4 | SEC ↗ |
| CHIEF DEVELOPMENT OFFICER | Sale | 4,331 | $58K | Nov 26 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 5,296 | $71K | Nov 26 | SEC ↗ | |
Piekos BrianFirst filing | Chief Financial Officer | Sale | 4,471 | $60K | Nov 26 | SEC ↗ |
| CHIEF EXECUTIVE OFFICER | Sale | 10,940 | $147K | Nov 26 | SEC ↗ | |
Audhya Paul K.First filing | CHIEF MEDICAL OFFICER | Sale | 3,075 | $45K | Nov 19 | SEC ↗ |
| CHIEF EXECUTIVE OFFICER | Sale | 4,466 | $65K | Nov 19 | SEC ↗ | |
Yea ChristopherFirst filing | CHIEF DEVELOPMENT OFFICER | Sale | 2,683 | $39K | Nov 19 | SEC ↗ |
| CHIEF EXECUTIVE OFFICER | Sale | 3,328 | $38K | Nov 13 | SEC ↗ | |
Palleiko Benjamin LFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 7,294 | $116K | Sep 9 | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does KALV have?
KalVista Pharmaceuticals, Inc. (KALV) has 45 SEC Form 4 filings (93 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Jun 11, 2026.
When was the most recent SEC Form 4 filing for KALV?
The most recent Form 4 filing for KALV on Tracefour is dated Jun 11, 2026.
Who is the most active insider at KALV?
The most active SEC Form 4 filer at KALV in the rolling window is CHIEF EXECUTIVE OFFICER Palleiko Benjamin L, with 13 filings.
What is the net insider flow at KALV over the last 6 months?
Over the trailing 180 days, insiders at KALV have net sold $6.4M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at KALV in the current window?
Inside the rolling window, insiders at KALV bought $0 and sold $7.2M based on SEC Form 4 filings.
Can I get alerts for KALV insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at KalVista Pharmaceuticals, Inc. (KALV). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
KalVista Pharmaceuticals, Inc. is in the Healthcare sector.